Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 7/20 | 0.32 |
| ▸ | JAK1 | P23458 | 7/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258062 | 1.00 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1JAK2JAK1CCR6 | |
| SCHEMBL24258069 | 0.86 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL24258068 | 0.78 | L3MBTL1 (0.33) | L3MBTL1JAK2JAK1TYK2JAK3 | |
| SCHEMBL24258065 | 0.76 | JAK2 (0.56) | JAK2JAK1CCR6TYK2JAK3 | |
| SCHEMBL13243667 | 0.75 | JAK2 (0.33) | JAK2JAK1TYK2JAK3 | |
| Phosphoric Acid SCHEMBL29378441 | 0.71 | JAK2 (0.59) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL29837340 | 0.70 | JAK1 (0.61) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25035697 | 0.70 | JAK2 (0.32) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL23322330 | 0.69 | MET (0.47) | JAK2JAK3 | |
| SCHEMBL4107778 | 0.68 | JAK1 (0.38) | L3MBTL1JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322787-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2022036030-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322787-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 2276/4885L3MBTL1 4153/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.